86 - HCV Microelimination: Potential for Global Impact

Speaker(s)

• 

  Oluwaseun Falade-Nwulia, MBBS ,MPH

  Assistant Professor
  Johns Hopkins
  Baltimore, MD

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• 

  Gail Matthews, MBChB, MRCP, FRACP, PHD

  Associate Professor
  Kirby Institute

  Disclosure: Abbvie Inc : Grant/Research Support (Status: Ongoing); Gilead Sciences : Grant/Research Support (Status: Ongoing)
• BN

  Brianna Norton, DO, MPH

  Assistant Professor
  Montefiore Medical Center
  New York, New York

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit

No CPE Credits

Learning Objectives:

• discuss successful strategies for microelimination of HCV infection in people with HIV infection
• discuss successful strategies for microelimination of HCV infection in people who inject drugs
• discuss acute HCV infection and how management and nomenclature has changed in the DAA era

Presentations:

• 2:45pm – 4:00pm EDT

  Acute HCV Infection- is That Still a Thing?
  Gail Matthews, MBChB, MRCP, FRACP, PHD – Kirby Institute
• 2:45pm – 4:00pm EDT

  Microelimination of HCV Infection in People Who Inject Drugs
  Brianna L. Norton, DO, MPH – Montefiore Medical Center
• 2:45pm – 4:00pm EDT

  Microelimination of HCV Infection in People with HIV Infection
  Oluwaseun Falade-Nwulia, MBBS ,MPH – Johns Hopkins